Capstone Therapeutics Corp. (CAPS)
USD 2.08
(-11.49%)
USD 2.08
(-11.49%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 50.26 Million USD | 57.66% |
| 2022 | 31.88 Million USD | 0.33% |
| 2021 | 31.77 Million USD | 23.32% |
| 2020 | 25.76 Million USD | 509.75% |
| 2019 | 4.22 Million USD | 55.31% |
| 2018 | 2.72 Million USD | 11.15% |
| 2017 | 2.44 Million USD | 87.73% |
| 2016 | 1.3 Million USD | 3.41% |
| 2015 | 1.26 Million USD | 347.16% |
| 2014 | 282 Thousand USD | 182.0% |
| 2013 | 100 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 26.35 Million USD | -2.29% |
| 2024 Q1 | 26.96 Million USD | -46.35% |
| 2023 Q3 | 32.18 Million USD | -5.2% |
| 2023 FY | 50.26 Million USD | 57.66% |
| 2023 Q1 | 35.34 Million USD | 10.86% |
| 2023 Q2 | 33.94 Million USD | -3.95% |
| 2023 Q4 | 50.26 Million USD | 56.2% |
| 2022 Q4 | 31.88 Million USD | -9.37% |
| 2022 Q3 | 35.17 Million USD | -13.96% |
| 2022 FY | 31.88 Million USD | 0.33% |
| 2022 Q1 | 40.28 Million USD | 15.14% |
| 2022 Q2 | 40.88 Million USD | 1.48% |
| 2021 Q3 | 34.1 Million USD | 0.81% |
| 2021 Q4 | 34.99 Million USD | 2.61% |
| 2021 Q1 | 37.88 Million USD | 47.04% |
| 2021 FY | 31.77 Million USD | 23.32% |
| 2021 Q2 | 33.82 Million USD | -10.72% |
| 2020 Q4 | 25.76 Million USD | 15.85% |
| 2020 FY | 25.76 Million USD | 509.75% |
| 2020 Q3 | 22.24 Million USD | 0.0% |
| 2019 Q3 | 4.22 Million USD | 22.03% |
| 2019 Q4 | 4.22 Million USD | 0.0% |
| 2019 FY | 4.22 Million USD | 55.31% |
| 2019 Q1 | 3.31 Million USD | 21.87% |
| 2019 Q2 | 3.46 Million USD | 4.43% |
| 2018 FY | 2.72 Million USD | 11.15% |
| 2018 Q4 | 2.72 Million USD | -3.92% |
| 2018 Q3 | 2.83 Million USD | 8.84% |
| 2018 Q2 | 2.6 Million USD | 4.0% |
| 2018 Q1 | 2.5 Million USD | 2.21% |
| 2017 FY | 2.44 Million USD | 87.73% |
| 2017 Q1 | 1.39 Million USD | 6.67% |
| 2017 Q2 | 1.47 Million USD | 5.9% |
| 2017 Q3 | 2.35 Million USD | 59.67% |
| 2017 Q4 | 2.44 Million USD | 4.08% |
| 2016 FY | 1.3 Million USD | 3.41% |
| 2016 Q4 | 1.3 Million USD | -4.75% |
| 2016 Q3 | 1.36 Million USD | -4.33% |
| 2016 Q2 | 1.43 Million USD | 13.03% |
| 2016 Q1 | 1.26 Million USD | 0.4% |
| 2015 FY | 1.26 Million USD | 347.16% |
| 2015 Q4 | 1.26 Million USD | 570.74% |
| 2015 Q2 | 351 Thousand USD | -3.84% |
| 2015 Q1 | 365 Thousand USD | 29.43% |
| 2015 Q3 | 188 Thousand USD | -46.44% |
| 2014 Q3 | 471 Thousand USD | 9.53% |
| 2014 Q4 | 282 Thousand USD | -40.13% |
| 2014 FY | 282 Thousand USD | 182.0% |
| 2014 Q1 | 288 Thousand USD | 188.0% |
| 2014 Q2 | 430 Thousand USD | 49.31% |
| 2013 Q2 | 101 Thousand USD | -69.76% |
| 2013 FY | 100 Thousand USD | 0.0% |
| 2013 Q4 | 100 Thousand USD | -51.46% |
| 2013 Q3 | 206 Thousand USD | 103.96% |
| 2013 Q1 | 334 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -183124.584% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -431.0% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 30.643% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -6114.685% |
| Rebus Holdings, Inc. | 5.24 Million USD | -858.871% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 14.827% |
| Qrons Inc. | 1.48 Million USD | -3276.339% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -3999.125% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 32.91% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -112357.491% |
| Skye Bioscience, Inc. | 14.07 Million USD | -257.186% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 5.705% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -424.566% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -11823.106% |
| SQZ Biotechnologies Company | 50.03 Million USD | -0.45% |
| Intellipharmaceutics International Inc. | 12 Million USD | -318.561% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -1205.076% |
| Mesoblast Limited | 188.44 Million USD | 73.327% |
| Marizyme, Inc. | 26.67 Million USD | -88.426% |
| Genus plc | 485 Million USD | 89.636% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -760.299% |
| Pharming Group N.V. | 244.07 Million USD | 79.406% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -2400.535% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -1897.514% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -1222.737% |
| ContraFect Corporation | 32.53 Million USD | -54.511% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -2436.91% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -1213.182% |
| IMV Inc. | 37.93 Million USD | -32.508% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -326.755% |
| MultiCell Technologies, Inc. | 1617.67 USD | -3107085.025% |
| ONE Bio Corp. | 27.49 Million USD | -82.806% |
| Accustem Sciences Inc. | 1.07 Million USD | -4557.356% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 35.074% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -2276.471% |
| Q BioMed Inc. | 8.13 Million USD | -518.03% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 39.394% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -876.752% |
| Biomind Labs Inc. | 1.49 Million USD | -3254.037% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 57.663% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -455.883% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -173.123% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -3405.5% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -35273.518% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -24892.542% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -774.792% |
| GB Sciences, Inc. | 5.41 Million USD | -827.798% |
| Alpha Cognition Inc. | 7.16 Million USD | -601.543% |
| HST Global, Inc. | 593.59 Thousand USD | -8367.755% |
| CSL Limited | 18.62 Billion USD | 99.73% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -3891.763% |
| Halberd Corporation | 728.71 Thousand USD | -6797.583% |
| Enzolytics Inc. | 365.26 Million USD | 86.239% |
| Agentix Corp. | 2.51 Million USD | -1902.107% |
| Resverlogix Corp. | 67.39 Million USD | 25.42% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -5892.856% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 88.703% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -2832.555% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -103.119% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -322.277% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -1271.398% |
| AVAX Technologies, Inc. | 3.99 Million USD | -1158.568% |
| Zenith Capital Corp. | 27.56 Thousand USD | -182220.723% |
| Genscript Biotech Corporation | 1.32 Billion USD | 96.209% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -20961.453% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -1246.006% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -7282.71% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -1753.638% |
| Kadimastem Ltd | 3.5 Million USD | -1334.12% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -75000.48% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -216.033% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -10716.464% |
| LadRx Corporation | 2.2 Million USD | -2184.179% |
| Cell Source, Inc. | 15.8 Million USD | -217.991% |
| Regen BioPharma, Inc. | 5.45 Million USD | -820.988% |
| Regen BioPharma, Inc. | 5.45 Million USD | -820.988% |
| NovAccess Global Inc. | 7.86 Million USD | -539.432% |
| Affymax, Inc. | 8.87 Million USD | -466.61% |
| Itoco Inc. | 1.65 Million USD | -2940.497% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -2350.032% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -730.947% |
| Mobile Lads Corp. | 1.31 Million USD | -3726.731% |
| CytoDyn Inc. | 127.89 Million USD | 60.699% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -120151.681% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -3108.934% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -355.072% |
| SYBLEU INC | 681.41 Thousand USD | -7276.437% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -723.743% |
| International Stem Cell Corporation | 5.27 Million USD | -852.511% |
| Bioxytran, Inc. | 3.24 Million USD | -1446.823% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -7931.844% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -988.643% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -22.607% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -125.753% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -2381.699% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -817.561% |
| Neutra Corp. | 973.52 Thousand USD | -5063.072% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -73.235% |
| PureTech Health plc | 125.58 Million USD | 59.975% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -1237.831% |
| IXICO plc | 1.9 Million USD | -2545.067% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -144.844% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 51.353% |
| CSL Limited | 18.62 Billion USD | 99.73% |
| Cellectis S.A. | 249.36 Million USD | 79.844% |